Published in J Biol Chem on February 14, 2013
The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol (Dordr) (2016) 0.89
A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP. Oncogenesis (2013) 0.89
MT-LOOP-dependent localization of membrane type I matrix metalloproteinase (MT1-MMP) to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem (2013) 0.87
Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo. Oncotarget (2016) 0.82
Protein interference applications in cellular and developmental biology using DARPins that recognize GFP and mCherry. Biol Open (2014) 0.80
MT1-MMP sheds LYVE-1 on lymphatic endothelial cells and suppresses VEGF-C production to inhibit lymphangiogenesis. Nat Commun (2016) 0.79
New strategies for targeting matrix metalloproteinases. Matrix Biol (2015) 0.77
Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed) (2015) 0.76
Matrix metalloproteinase 14 participates in corneal lymphangiogenesis through the VEGF-C/VEGFR-3 signaling pathway. Exp Ther Med (2016) 0.75
Reciprocal relationship between membrane type 1 matrix metalloproteinase and the algesic peptides of myelin basic protein contributes to chronic neuropathic pain. Brain Behav Immun (2016) 0.75
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas. PLoS One (2016) 0.75
Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis. Oncotarget (2016) 0.75
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem (2017) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
A better cell line for making hybridomas secreting specific antibodies. Nature (1978) 15.13
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 6.40
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
The structural basis for red fluorescence in the tetrameric GFP homolog DsRed. Nat Struct Biol (2000) 4.55
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol (2004) 4.16
Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem (1997) 3.74
Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem (1997) 3.09
Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet (2001) 2.81
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Progress in matrix metalloproteinase research. Mol Aspects Med (2008) 2.51
Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A (1995) 2.25
Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J (2001) 2.23
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem (1993) 1.83
TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem (1998) 1.59
Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet (2007) 1.56
Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods (2008) 1.55
A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem (2006) 1.52
MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem (2007) 1.51
Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer (1995) 1.48
Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem (1995) 1.41
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol (2004) 1.35
Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J Biol Chem (2007) 1.25
Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol (2007) 1.23
A new acid mucopolysaccharidosis with skeletal deformities simulating rheumatoid arthritis. Am J Roentgenol Radium Ther Nucl Med (1969) 1.21
MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene (2007) 1.19
Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res (1999) 1.11
Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res (2001) 1.09
The non-phagocytic route of collagen uptake: a distinct degradation pathway. J Biol Chem (2011) 1.09
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem Res Int (2010) 1.07
Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. Int J Cancer (2002) 1.06
Recombinant interferon-gamma secreted by Chinese hamster ovary-320 cells cultivated in suspension in protein-free media is protected against extracellular proteolysis by the expression of natural protease inhibitors and by the addition of plant protein hydrolysates to the culture medium. In Vitro Cell Dev Biol Anim (2005) 1.05
MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. Oncogene (2011) 0.98
Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood (2012) 0.96
Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res (2003) 0.94
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. Biol Chem (2008) 0.92
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther (2008) 0.92
Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome. Am J Hum Genet (2012) 0.91
Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci (2007) 0.91
A novel functional role of collagen glycosylation: interaction with the endocytic collagen receptor uparap/ENDO180. J Biol Chem (2011) 0.90
Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Int J Biochem Cell Biol (2011) 0.88
Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods (1999) 0.88
MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch (1996) 0.87
Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13. Biochemistry (2012) 0.82
Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells. Cancer Lett (2007) 0.81
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol (2004) 4.16
Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene (2002) 2.74
MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol (2004) 2.45
Plasminogen activation and cancer. Thromb Haemost (2005) 2.21
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J (2005) 2.12
Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol (2009) 1.99
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood (2010) 1.82
Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med (2002) 1.81
Intramolecular migration of amide hydrogens in protonated peptides upon collisional activation. J Am Chem Soc (2005) 1.77
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol (2003) 1.60
MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med (2005) 1.55
MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem (2007) 1.51
An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev (2005) 1.47
MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell (2009) 1.46
Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol (2005) 1.42
The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res (2013) 1.35
Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat Protoc (2013) 1.33
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene (2004) 1.33
Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis (2007) 1.32
Membrane-type 1 matrix metalloproteinase is required for normal alveolar development. Dev Dyn (2005) 1.32
Targeting the tumor microenvironment for cancer therapy. Clin Chem (2012) 1.32
Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res (2010) 1.26
Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J Biol Chem (2007) 1.25
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp Cell Res (2004) 1.23
Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol (2007) 1.23
Complementary roles of intracellular and pericellular collagen degradation pathways in vivo. Mol Cell Biol (2007) 1.22
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.21
Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem (2002) 1.21
M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol (2013) 1.19
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem (2004) 1.18
Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer (2006) 1.16
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem (2010) 1.14
Plasmodium ookinetes coopt mammalian plasminogen to invade the mosquito midgut. Proc Natl Acad Sci U S A (2011) 1.13
ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Res (2008) 1.13
uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets (2011) 1.12
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int J Cancer (2002) 1.12
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer (2005) 1.12
Cysteine-rich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma. Biochemistry (2004) 1.10
The non-phagocytic route of collagen uptake: a distinct degradation pathway. J Biol Chem (2011) 1.09
Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J Biol Chem (2011) 1.09
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis (2005) 1.08
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res (2008) 1.08
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res (2002) 1.07
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia (2005) 1.06
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol (2012) 1.05
A novel formulation of inhaled doxycycline reduces allergen-induced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. Biochem Pharmacol (2007) 1.04
Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res (2010) 1.04
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem (2012) 1.03
Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol (2012) 1.03
The collagen receptor uPARAP/Endo180. Front Biosci (Landmark Ed) (2009) 1.02
Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry. Biochemistry (2004) 1.01
Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell (2013) 1.01
Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J (2007) 0.99
Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland. J Cell Physiol (2005) 0.99
Increased expression of the collagen internalization receptor uPARAP/Endo180 in the stroma of head and neck cancer. J Histochem Cytochem (2006) 0.98
Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J Immunol (2013) 0.97
Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood (2012) 0.96
Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination. Cancer Res (2013) 0.96
Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochem J (2004) 0.96
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol (2010) 0.96
Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization. Cell Mol Life Sci (2010) 0.94
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. Biol Chem (2008) 0.92
Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer (2003) 0.92
Loss of miR-10a activates lpo and collaborates with activated Wnt signaling in inducing intestinal neoplasia in female mice. PLoS Genet (2013) 0.91
Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci (2007) 0.91
Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma. Am J Respir Cell Mol Biol (2012) 0.91
Sunitinib inhibits inflammatory corneal lymphangiogenesis. Invest Ophthalmol Vis Sci (2013) 0.90
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol (2004) 0.90
No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancer. PLoS One (2012) 0.90
A novel functional role of collagen glycosylation: interaction with the endocytic collagen receptor uparap/ENDO180. J Biol Chem (2011) 0.90
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem (2008) 0.90
Membrane-type MMPs are indispensable for placental labyrinth formation and development. Blood (2010) 0.90